Clinical Trial Update: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

The document describes a Phase 2 clinical trial evaluating a four-drug regimen (blinatumomab, methotrexate, cytarabine, and ponatinib) for Philadelphia chromoso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• CYTARABINE (CYTARABINE)
• METHOTREXATE (METHOTREXATE)
• Ponatinib (ponatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING